Researchers discover way to save blood from ravages of chemo treatment
(Medical Xpress)—Chemotherapy kills blood cells as well as cancer cells, often with fatal results. Now Yale stem cell researchers have identified a method they hope one day will help cancer patients undergoing ...
Medical research
Oct 19, 2012 |
5 / 5 (1) |
0
Personalized antiplatelet treatment improves outcome after PCI
Personalized antiplatelet treatment leads to better outcomes than standard antiplatelet treatment in patients undergoing coronary stent implantation, according to results from the MADONNA study presented at ESC Congress 2012.
Cardiology
Aug 28, 2012 |
not rated yet |
0
Pre-op eltrombopag reduces need for platelet transfusions
(HealthDay)—For patients with chronic liver disease who require an invasive procedure as part of their routine care, the oral thrombopoietin-receptor agonist eltrombopag reduces the need for platelet transfusions, ...
Diseases, Conditions, Syndromes
Aug 23, 2012 |
not rated yet |
0
|
Adult stem cells from liposuction used to create blood vessels in the lab
Adult stem cells extracted during liposuction can be used to grow healthy new small-diameter blood vessels for use in heart bypass surgery and other procedures, according to new research presented at the American Heart Association's ...
Cardiology
Jul 25, 2012 |
not rated yet |
0
Improved survival for patients with chronic blood diseases
(Medical Xpress) -- New research from Karolinska Institutet shows that the survival for patients with chronic myeloproliferative diseases has improved in recent decades. This is despite the fact that no targeted drugs have ...
Cancer
Jul 17, 2012 |
not rated yet |
0
New platelet blocker reduces blood clots, artery-opening procedures
A new investigational platelet blocker reduces the rate of clotted arteries and the need for artery-opening revascularization procedures in the legs in people with peripheral artery disease (PAD), according to new research ...
Cardiology
Jun 21, 2012 |
not rated yet |
0
Plavix's new generic status could be boon for patients
(HealthDay) -- The blockbuster drug Plavix (clopidogrel), used to prevent clotting in some heart patients, will go off patent in the United States on Thursday, making it considerably more affordable.
Medications
May 15, 2012 |
not rated yet |
0
Rituximab promotes long-term response for patients with immune destruction of platelets
A new analysis concludes that rituximab, a drug commonly used to treat blood cancers, leads to treatment responses lasting at least five years in approximately one quarter of patients with low platelet counts and a risk of ...
Pediatrics
May 07, 2012 |
not rated yet |
0
Study reports validation of the first point-of-care genetic test in medicine, regarding use of antiplatelet therapy
A study published Online First by the Lancet reports the successful validation and clinical application of the first point-of-care genetic test in medicine. The test successfully identifies the CYP2C19*2 allele: a common ...
Cardiology
Mar 28, 2012 |
not rated yet |
0
|
Ticagrelor effective at reducing first, as well as recurrent and overall cardiovascular events
Ticagrelor, a potent anti-platelet medication, was approved by the Food and Drug Administration in the summer of 2011 and is known to significantly reduce the risk of stroke, heart attack, vascular death and death overall ...
Cardiology
Mar 26, 2012 |
not rated yet |
0
Platelet inhibitor reduces size of large heart attacks
The anti-platelet drug abciximab, delivered directly to lesions caused by a heart attack, significantly decreased damage to the heart muscle in high-risk patients while clot aspiration showed no impact, according to research ...
Cardiology
Mar 26, 2012 |
not rated yet |
0
|
New class of platelet blockers proves effective in phase III trial
Adding vorapaxar, an investigational platelet blocker, to standard antiplatelet therapy significantly reduces the risk of recurrent cardiovascular events in patients with known atherosclerosis, a hardening and narrowing of ...
Cardiology
Mar 26, 2012 |
not rated yet |
0
|
Merck blood thinner shows mixed results: study
An experimental blood thinning drug made by the pharmaceutical giant Merck may reduce the risk of dying from a heart attack but also boosts the danger of internal bleeding, researchers said Saturday.
Cardiology
Mar 24, 2012 |
not rated yet |
0
Aspirin enhances platelet isoprostanes in type 2 diabetes
(HealthDay) -- For patients with type 2 diabetes mellitus (T2DM) who are treated with aspirin, isoprostanes are overproduced, which is linked with enhanced platelet recruitment, according to a study published ...
Diabetes
Mar 23, 2012 |
not rated yet |
0
Solving the mystery of blood clotting
How and when our blood clots is one of those incredibly complex and important processes in our body that we rarely think about. If your blood doesn't clot and you cut yourself, you could bleed to death, if ...
Medical research
Mar 19, 2012 |
5 / 5 (1) |
0
|
